drugset / Trial / NCT01855529

ROPI Study : Ropivacaine Interest in Postsurgical Pain After Mastectomy

NCT01855529

Phase 2 Completed 150 enrolled Centre Jean Perrin
RandomizedParallel-groupDouble-blindTreatment

Summary

After surgery for breast cancer, the prevalence of chronic pain is estimated between 20 and 68%. They begin after surgery and may persist until more than 6 months. They respond poorly to opioid analgesics impair the quality of life. Among the different postoperative analgesic techniques used, the use of a local anesthetic infiltration continues catheter has advantages including improving the quality of analgesia, with a significant decrease in average of VAS (scale visual Analogue), a decrease in morphine consumption, improving the quality of life of patients. Our study aims to evaluate the effectiveness of a continuous local anesthetic infiltration in the control of postoperative pain after mastectomy.

Timeline

Start
2013-04
Primary completion
2016-08
Completion
2016-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Ropivacaine Other / unclassified 2 mg/ml Other

Indications

No indication recorded.